NCT06173089

Brief Summary

However, the current guidelines recommend the use of remote monitoring (RM) in patients with cardiac implantable electronic devices (CIED) to reduce inappropriate shocks or early detection of atrial fibrillation, data is incomprehensive on the effectiveness of decreasing heart failure events or mortality in patients with heart failure and reduced ejection fraction (HFrEF). The only randomized trial, which proved the efficacy of RM on mortality was the IN-TIME trial, which used a strict protocol for detection and intervention of the heart failure events. The primary aim of this study is to optimize the use of remote monitoring system in HFrEF patients already implanted an implantable cardiac defibrillator (ICD) or a cardiac resynchronization therapy (CRT). By creating a high-quality system with structured safety-net, which is able to use the data of remote monitoring messages and alerts of our patients, we can improve their outcome. The primary endpoint is the non-fatal heart failure event or all-cause mortality. Secondary outcomes include all-cause mortality, cardiovascular mortality, heart failure hospitalization, cardiovascular hospitalization, unscheduled visits, af burden, stroke, inappropriate shocks, quality of life, NYHA functional class. By using artificial intelligence-based methods, the optimal cut-off values of the previously, empirically used alert parameters will be validated or challenged. Additionally, cost-effectiveness to reduce the hospitalizations will be calculated. Due to this remote monitoring structured safety-net, these patients with severe heart failure can be treated more efficiently, safely and cost-effectively.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
800

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 30, 2023

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

November 28, 2023

Completed
17 days until next milestone

First Posted

Study publicly available on registry

December 15, 2023

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2025

Completed
Last Updated

December 15, 2023

Status Verified

January 1, 2023

Enrollment Period

2.4 years

First QC Date

November 28, 2023

Last Update Submit

December 7, 2023

Conditions

Keywords

remote monitoringhome monitoringheart failurecardiac resynchronization therapyimplantable cardioverter defibrillator

Outcome Measures

Primary Outcomes (1)

  • The composite of all-cause mortality, heart failure events

    12 months

Secondary Outcomes (3)

  • cardiovascular mortality

    12 months

  • cardiovascular hospitalization

    12 months

  • unscheduled visits

    12 months

Other Outcomes (2)

  • Change in Kansas City Cardiomyopathy Questionnaire score

    12 months

  • change of symptoms (assessed by NYHA classification)

    12 months

Interventions

Remote monitoring for patients with an ICD/CRT device

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

chronic heart failure with reduced ejection fraction (HFrEF) with an implanted CIED (CRT/ICD) eligible for home monitoring

You may qualify if:

  • CRT-P/CRT-D patients with a feasible device for home monitoring
  • ICD (VVI/VDD/DDD) patients with a feasible device for home monitoring
  • SR/AFib
  • Transmission performance \>80% in the first 2 weeks with new device
  • Informed consent

You may not qualify if:

  • Life expectancy\<1 year
  • Unable to transmit data
  • Patient is unable to visit the physician/clinic in 12 hours when it is indicated by the alerts
  • Expected non-compliance
  • Pregnancy
  • Known drug, alcohol abuse
  • Participation in other study or HM system concept

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Semmelweis University - Heart and Vascular Center

Budapest, 1122, Hungary

RECRUITING

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 28, 2023

First Posted

December 15, 2023

Study Start

January 30, 2023

Primary Completion

June 30, 2025

Study Completion

August 30, 2025

Last Updated

December 15, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will share

Locations